SAN MATEO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 21st Annual Piper Jaffray Health Care Conference, to be held December 1-2, 2009 at The New York Palace Hotel in New York, New York.
Event: 21st Annual Piper Jaffray Health Care Conference
Date: Wednesday, December 2, 2009
Time: 11:00 a.m. ET
Place: The New York Palace Hotel, NYC (Holmes 1: 4th Floor)
About NeurogesX, Inc.
NeurogesX, Inc. is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.
The Company’s second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the safety and efficacy of Qutenza(TM); the timing of launch of Qutenza; and development activities for NGX-1998 and other product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: any regulatory approvals which are received may be limited to certain indications; Qutenza and NeurogesX’ other product candidates may have unexpected adverse side effects; difficulties or delays in the launch and commercialization of Qutenza; and the outcomes of any submissions to the FDA for NeurogesX’ products and product candidates. For further information regarding these and other risks related to NeurogesX’ business, investors should consult NeurogesX’ filings with the Securities and Exchange Commission.
CONTACT: Stephen Ghiglieri, Chief Financial Officer, NeurogesX, Inc.,
+1-650-358-3310; Investors Contact: Sara Pellegrino, The Ruth Group,
+1-646-536-7002, spellegrino@theruthgroup.com; Media Contact: Jason Rando,
+1-646-536-7025, jrando@theruthgroup.com
Web site: http://www.neurogesx.com/
